Diagnovus News

James Stover at Diagnovus in Nashville announced a new cancer-related assay today, in the first offering for the 10-year-old lifescience startup. Their release is here.

GTx distress frees cancer drug

An adverse FDA ruling against GTx may actually have helped spur the Memphis company to take a useful anti-breast cancer drug, Fareston, off the shelf and market it more aggressively as an alternative to Tamoxifen. The CA reports.

Biopharma: GTx, Provectus report progress

Memphis-based GTx and Knoxville-based Provectus reported gains toward development of key products.

Vanderbilt scientists seen potential cancer therapy gains

Vanderbilt University Medical Center scientists have found a new use for an old drug for treating pinworms in studying signaling pathways important to human early development and the onset of cancer. The Reporter has it.

B'ham Vivo BioScience in Roche-ACEA pact

Birmingham Vivo Bioscience announced entering an R&D collaboration for development of cell-based assays for the xCELLigence System, co-developed by Roche-ACEA and marketed by Roche Applied Science. Details here. The B'ham BJ says the deal is worth about $2MM now for Vivo.

Humanity Ascending | Vanderbilt Magazine

Vanderbilt Magazine offers vignette's of graduates who have followed their passions to serve humankind in the U.S. and in developing nations. These inspiring samples are here.

Cancer-detection breakthrough

As the 70-year-old CEO of EDP Biotech Corp. in Knoxville, Tom Boyd (at left, in shirt from another venture) must be an interesting guy, and his firm probably deserves the sudden buzz they're getting, as a result of their announcement Friday, which read in part, saying the company has introduced a "revolutionary new technology for a simple blood test to detect early-stage colon cancer. Following the success of its pre-clinical trials for the ColoMarker™ assay, EDP has filed a patent on the biomarker, CA11-19, and all aspects of its use. Via an inexpensive blood test, ColoMarker™ will detect colon cancer in its earliest, most curable stages."

NeoGenomics appointment

NeoGenomics Inc. (NASD OTC BB: NGNM), the Fort Myers, Fla.-based company that has a cancer genetics diagnostic lab in Nashville's Grassmere Park, announced it's named Jack Spitz vice president over lab operations. Spitz was previously in charge of operations for Orlando, Fla.-based Dermpath Diagnostics, a division of Quest Diagnostics.

GeneIndexer breakthrough

Memphis-based Computable Genomix LLC, formed in 2007 after about four years concerted work by a couple of Memphis-area informatics experts, is launching GeneIndexer, which the company and its beta customers say drastically reducing the time spent on sorting genomic information for the data most useful in studies. The CA reports.